Novel 4′-Substituted Stavudine Analog with Improved Anti-Human Immunodeficiency Virus Activity and Decreased Cytotoxicity
Open Access
- 1 May 2004
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (5), 1640-1646
- https://doi.org/10.1128/aac.48.5.1640-1646.2004
Abstract
The antiviral drug 2′,3′-didehydro-3′-deoxythymidine (D4T; also know as stavudine and Zerit), which is used against human immunodeficiency virus (HIV), causes delayed toxicity (peripheral neuropathy) in long-term use. After examining a series of 2′,3′-didehydro-3′-deoxy-4′-substituted thymidine (4′-substituted D4T) analogs, 4′-ethynyl D4T was found to have a fivefold-better antiviral effect and to cause less cellular and mitochondrial toxicity than D4T. The antiviral activity of this compound can be reversed by dThd but not by dCyd. The compound acted synergistically with β- l -2′,3′-deoxy-3′-thiacytidine (also known as lamivudine) and β- l -2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine (also known as elvucitabine) and additively with 2′,3′-dideoxyinosine (also known as didanosine and Videx) and 3′-azido-3′-deoxythymidine (also known as Retovir and zidovudine) against HIV. 4′-Ethynyl D4T is phosphorylated by purified human thymidine kinase 1 (TK-1) from CEM cells with a faster relative V max and a lower K m value than D4T. The efficiency of TK-1 in the phosphorylation of 4′-ethynyl D4T is fourfold better than that of D4T. While D4T is broken down by the catabolic enzyme thymidine phosphorylase, the level of breakdown of 4′-ethynyl D4T was below detection. Since 4′-ethynyl D4T has increased anti-HIV activity and decreased toxicity and interacts favorably with other currently used anti-HIV drugs, it should be considered for further development as an anti-HIV drug.Keywords
This publication has 38 references indexed in Scilit:
- Synthesis of a highly active new anti-HIV agent 2′,3′-Didehydro-3′-deoxy-4′-ethynylthymidineBioorganic & Medicinal Chemistry Letters, 2003
- Insights into the Molecular Mechanism of Mitochondrial Toxicity by AIDS DrugsJournal of Biological Chemistry, 2001
- Long-Term Exposure of HIV Type 1-Infected Cell Cultures to Combinations of the Novel Quinoxaline GW420867X with Lamivudine, Abacavir, and a Variety of Nonnucleoside Reverse Transcriptase InhibitorsAIDS Research and Human Retroviruses, 2000
- Adverse effects of reverse transcriptase inhibitorsAIDS, 1998
- Synthesis and Biological Evaluation of 2',3'-Dideoxy-L-pyrimidine Nucleosides as Potential Antiviral Agents against Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV)Journal of Medicinal Chemistry, 1994
- 2',3'-Didehydro-3'-deoxythymidine (d4T) in Patients with AIDS or AIDS-Related Complex: A Phase I TrialThe Journal of Infectious Diseases, 1993
- Synthesis and anti-HIV activity of 4'-azido- and 4'-methoxynucleosidesJournal of Medicinal Chemistry, 1992
- Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complexThe Lancet, 1990
- Nature, time course and dose dependence of zidovudine-related side effectsAIDS, 1989
- The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987